QTERNMET XR
PeakNDAORALTABLET, EXTENDED RELEASE
Approved
May 2019
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
2/8 — Basic
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QTERNMET XR is an oral extended-release tablet approved by the FDA on May 2, 2019, as a small-molecule NDA from AstraZeneca. The specific indication and mechanism of action are not disclosed in available data. Based on the brand name containing 'MET', this likely relates to a metformin-based combination therapy, though clinical details remain proprietary.
Peak4.5 years to LOE
At peak lifecycle stage with high competitive pressure (8/10), indicating mature market with active commercial infrastructure and potentially larger sales teams defending market share.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on QTERNMET XR at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.